The NASH Summit offers a wide range of cutting-edge debates across 4 conference tracks: discovery, translational, non-invasive biomarker and clinical drug development, in addition to a selection of workshops and seminars. This convivial discussion and networking forum has an extensive program set to help you approach your pipeline for the upcoming year.

Join 80+ speakers, including our conference Chair Jason Campagna, Senior Vice President & Global NASH Lead at Intercept, and 350+ attendees as the community comes together aga Mayin by addressing their challenges and the consequences of change in the NASH market.

• Establish a plan of action to optimize candidate success by evaluating advances and difficulties and learn from the community’s experience
• Translate anti-fibrotic efficacy into the clinic by learning about ground-breaking preclinical modalities
• Use the latest practical insights into hepatocyte differentiation to improve your target identification by understanding its impact on immune cells, ductular reaction and fibrosis
• Examine the payer’s thoughts on the need to biopsy and assess the clinical utility of non-invasive diagnostics in the normal algorithm of care
• Connect NASH reduction in phase 2 and NASH resolution in phase 3 while justifying a systemic approach to address NASH in combination, as a manifestation of wider metabolic dysfunction

Download the full event guide or get in touch today for the agenda and speaker line-up!